Map of the HAT foci in Guinea.

Endemic transmission foci in red, old foci with last cases reported before 2004 in orange, zones at risk in yellow, Atlantic Ocean in blue. This map was elaborated in-house with QGIS 3.28.12 from an OSM standard layer (www.openstreetmap.org).</p

Usage and performance of Coris HAT Sero-K-SeT for D2D active screening in Guinea from 2019 to 2021.

Usage and performance of Coris HAT Sero-K-SeT for D2D active screening in Guinea from 2019 to 2021.</p

False positive results with Abbott Bioline HAT 2.0 in malaria-RDT negative vs. positive subjects in Friah (Local Health Center, September 2021) and Conakry (Saint Gabriel Dispensary, October-November 2021).

False positive results with Abbott Bioline HAT 2.0 in malaria-RDT negative vs. positive subjects in Friah (Local Health Center, September 2021) and Conakry (Saint Gabriel Dispensary, October-November 2021).</p

Current algorithm used by the HAT-NCP to detect HAT cases by active screening in Guinea.

Current algorithm used by the HAT-NCP to detect HAT cases by active screening in Guinea.</p

Usage and performance of SD Bioline HAT for D2D active screening in Guinea from 2016 to 2020.

Usage and performance of SD Bioline HAT for D2D active screening in Guinea from 2016 to 2020.</p

Usage of the different HAT-RDTs for door-to-door active medical surveys from 2016 to 2021 in Guinea.

The evolution of the total annual number of HAT cases detected by both passive and active surveillance is shown on the upper graph. Different strategies have been successively implemented according to the availability and cost of the different RDTs. From 2016 to 2018, SD Bioline HAT was applied (details in Table 1). From 2019 to mid-2021, HAT Sero-K-SeT was used either alone, or in combination with SD Bioline HAT then with Abbott Bioline HAT 2.0 (details Table 2). From mid-2021 to date, Abbott Bioline HAT 2.0 was applied alone, then with HAT Sero-K-SeT used as secondary test (details in Table 3). The positivity rates (number of positive RDTs / number of screened individuals) were only calculated for RDTs used as first line tests. The Positive Predictive Values (PPVs) were calculated by combining results from primary and secondary RDTs.</p

Comparison of the sensitivity and specificity of HAT RDTs on frozen plasma samples from the HAT-NCP biobank (2017–2020) as compared to the initial parasitological diagnostic by mAECT and/or direct examination of lymph node aspirates.

Comparison of the sensitivity and specificity of HAT RDTs on frozen plasma samples from the HAT-NCP biobank (2017–2020) as compared to the initial parasitological diagnostic by mAECT and/or direct examination of lymph node aspirates.</p

Usage and performance of Abbott Bioline HAT 2.0 for D2D active screening in Guinea in 2021.

Usage and performance of Abbott Bioline HAT 2.0 for D2D active screening in Guinea in 2021.</p